GlassScriptPhysician profile
Terrence J Ihnat
NPI 1508814005
$860.17
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $135 · 2021: $128.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $269.51 | 2019-2020 | |
| Davol INC. | $159.86 | 2020-2021 | |
| Allergan, INC. | $138.63 | 2019 | |
| Covidien LP | $50.78 | 2019-2020 | |
| Acell, INC. | $44.77 | 2019 | |
| Smith+Nephew, INC. | $42.12 | 2019 | |
| Tei Biosciences INC | $33.40 | 2019 | |
| Intuitive Surgical, INC. | $33.05 | 2019-2020 | |
| Integra Lifesciences Corporation | $27.09 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $18.76 | 2019 | |
| Kci USA, INC. | $16.44 | 2019 | |
| Organogenesis INC. | $13.23 | 2019 | |
| Medline Industries LP | $12.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrence Ihnat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.